<DOC>
	<DOCNO>NCT00338910</DOCNO>
	<brief_summary>The primary objective study describe possible effect metronidazole PK budesonide healthy volunteer .</brief_summary>
	<brief_title>Pharmacokinetic Interaction Study Between Budesonide Metronidazole Healthy Volunteers</brief_title>
	<detailed_description>The primary objective study describe possible effect metronidazole PK budesonide healthy volunteer . Secondary objective : 1 . Effect budesonide metronidazole steady-state PK ( primarily describe area concentration-time-curve ) . 2 . Urinary 6β-hydroxycortisol ( marker CYP3A activity ) cortisol excretion metronidazole multiple-dose co-administration . 3 . Safety parameter .</detailed_description>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Healthy male subject Caucasian origin Age : 18 55 year ( inclusive ) Body mass index ( BMI ) within 1830 kg/m² Body weight least 50 kg , 100 kg Nonsmoker ( exsmoker ≥1 year ) , proven urine cotinine &lt; 500 ng/ml Clinically acceptable supine blood pressure pulse rate , i.e . BP 100145 mmHg systolic , 6090 mmHg diastolic pulse rate 50100 bpm Normal ECG Participants must perform adequate contraception study 6 month last dose present trial Ability communicate well investigator comply requirement entire study Written consent Subjects contraindication budesonide Subjects contraindication metronidazole History current clinical evidence cardiac , cardiovascular , pulmonary , gastrointestinal , ( cholangio ) hepatic , renal , endocrine , neurological , musculoskeletal , ophthalmological , infectious , haematological , oncological , psychiatric , acute chronic disease and/or pathological finding might interfere drug ' safety , tolerability , absorption and/or pharmacokinetics History current evidence clinically relevant allergy idiosyncrasy drug food Clinically relevant abnormality clinical chemical , hematological laboratory variable Current smoker exsmoker ≤ 1 year Excessive alcohol consumption ( ³ 35 g/day male ) Abuse drug Positive drug screen Positive antiHIVtest , HBsAgtest antiHCVtest Proneness orthostatic dysregulation , faintings , blackout Heavy tea coffee drinker ( 1 l ≈ 6 cup per day ) Administration glucocorticosteroids within 6 week prior study day 1 trial Repeated use drug last 4 week prior study day 1 trial , might influence hepatic biotransformation Any medication include OTC medication within last 14 day prior study day 1 trial ( single intake drug may accept judged investigator clinical relevance relevance study objective ) Intake grapefruitcontaining food beverage within 7 day prior study day 1 trial Clinically relevant acute chronic bacterial , fungal viral infection Surgery gastrointestinal tract may interfere drug absorption ( applicable minor abdominal surgery e.g . appendectomy herniotomy ) Vegetarian diet peculiar dietary habit would preclude subject 's acceptance standardize ( nonvegetarian ) meal Subjects suspect know follow instruction Subjects unable understand write verbal instruction , particular regard risk inconvenience expose result participation study Patients know financial difficulty , could interfere appraisal informative instruction Vulnerable subject ( e.g. , person keep detention person depend sponsor investigator ) Blood donation blood loss 400 ml within last 2 month prior study day 1 Participation clinical trial within last 2 month prior study day 1 ( assess anamnestic inquiry )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>healthy volunteer</keyword>
</DOC>